Benzodiazepine Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2020 to 2027

According to Vision Research Reports, the global benzodiazepine drugs market size is expected to hit US $ 2,630 million by 2027 and projected to expand at a CAGR of 3.2% between 2020 and 2027.

The benzodiazepine drugs market is projected to expand during the forecast period owing to the rise in prevalence of anxiety, seizures, and increase in concerns among people about preventive measures for stress-related conditions. Moreover, higher prescriptions for benzodiazepine drugs, as compared to other psychoactive drugs, and increase in rate of adoption of generic drugs are propelling the global benzodiazepine drugs market. North America is expected to dominate the global benzodiazepine drugs market due to more FDA approvals for benzodiazepine drugs in the region. Latin America and Asia Pacific are potential markets for benzodiazepine drugs. The market in Asia Pacific is projected to expand at a CAGR of 3.7% during the forecast period.

Increase in prevalence of anxiety disorders, insomnia, seizures and comparatively higher number of prescriptions for benzodiazepines to drive the global market

Rise in prevalence of anxiety and seizures is a major driver of the global benzodiazepine drugs market. Current lifestyle and urban life have made peoples’ lives more stressful, which leads to mental disorders such as depression, anxiety, panic, and maniac conditions. Psychoactive drugs, such as benzodiazepine, are required to relieve these conditions and attacks. For instance, according to WHO, in 2015, the total number of people living with anxiety disorders, globally, was 264 million. Similarly, higher number of prescriptions for benzodiazepines, as compared to other psychoactive drugs, and increase in rate of adoption of generic drugs are major drivers of the global benzodiazepine drugs market.

Alprazolam to be highly lucrative segment

Alprazolam is expanding segment of the benzodiazepine drugs market. It is projected to account for 29.40% share of the market, and expand at a CAGR of 3.1%, during the forecast period. The segment is anticipated to reach a value of US$ 768.09 Mn by 2027. Extensive utilization of Alprazolam in anxiety and panic disorders and higher number of prescriptions of Alprazolam for these conditions are likely to drive the segment of the global market during the forecast period.

Anxiety to be dominant segment

Anxiety was a dominant segment of the global benzodiazepine drugs market in 2017. It is expected to maintain its position during the forecast period. The segment is anticipated to reach a value of US$ 1,384.12 Mn by 2027. It is projected to account for 52.9% share of the market and expand at a CAGR of 3.2% during the forecast period. Benzodiazepine drugs are preferred to control the symptoms and general anxiety. Therefore, a rise in the prevalence of anxiety across the globe drives the segment. For instance, according to Anxiety and Depression Association of America (ADAA), around 40 million adults are affected every year with anxiety disorders, of which only 36.9% receive treatment.

Ultra-short Acting to be promising segment

In terms of time of action, the global market has been segmented into ultra-short acting, short acting, and long acting. The short acting segment held a major share of the global market in 2019. It is projected to maintain its leading position in the market during the forecast period. The short acting segment is projected to hold 77.1% share of the market by 2027. However, the ultra-short acting segment is anticipated to expand at a CAGR of 3.1% during the forecast period. Expansion of the segment can be attributed to the rise in popularity due to its pharmacokinetic activity and less chance for developing drug dependency.

Others distribution channel to be promising segment

In terms of distribution channel, the global market has been classified into hospital pharmacies, retail pharmacies and others. The retail pharmacies segment held a major share of the global market in 2017. It is estimated to maintain its position in the global market during the forecast period. The retail pharmacies segment is projected to hold 54.12% share of the market and expand at a CAGR of 2.8% during the forecast period. However, the others segment, which includes online pharmacies and mail pharmacies, is highly lucrative. It is expected to expand at a higher CAGR of 3.0% during the forecast period owing to better discount rates on online platforms and popularity owing to convenience.

North America expected to dominate global market

In terms of region, the global benzodiazepine drugs market has been segmented into five major regions as North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market in 2019. The market in North America is likely to expand at a CAGR of 2.2% during the forecast period. The market in North America was valued at US$ 781.73 Mn, and the region accounted for 38.8% share of the global market, in 2019. This was due to the rise in prevalence of anxiety, panic disorders, and higher FDA approvals for benzodiazepine drugs by major players in the region. The anxiety segment dominated the market in the region. It is projected to expand at a CAGR of 2.6% during the same period. Asia Pacific is a highly lucrative market. It is anticipated to expand at a CAGR of 3.5% during the forecast period due to a rise in the prevalence of anxiety disorders, seizures, increased awareness among people about healthcare, and rise in health care expenditure in the region.

Pfizer Inc. and F.Hoffmann La Roche Ltd. among major players in global market

The global benzodiazepine drugs market is fragmented in terms of number of players. Key players operating in the global market include Pfizer Inc., F.Hoffmann-La Roche Ltd., Bausch Health Companies, Inc., Mylan, N.V., Teva Pharmaceutical Industries Ltd. and H.Lundbeck A/S. More FDA approvals are received by these major players in North America for benzodiazepine drugs.

The report analyzes and forecasts the benzodiazepine drugs market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2020 to 2027. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level. For the region and all segments, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers' sales, price, revenue, cost and gross profit and their changes. What's more, we will display the main consumers, raw material manufacturers, distributors, etc.

This report first introduces the background of benzodiazepine drugs, including the definition, classification, application, industrial chain structure, industry overview, national policy and planning analysis of the industry, and the latest dynamic analysis. With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major benzodiazepine drugs companies.

Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of benzodiazepine drugs upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of benzodiazepine drugs and consumption, major regions and consumption, major global producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.

The report comprises a detailed value chain analysis, which provides a comprehensive view of the global benzodiazepine drugs market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.

The study provides a decisive view of the benzodiazepine drugs market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

The report provides size (in terms of volume and value) of benzodiazepine drugs market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.

The report concludes with the company profiles section that includes key information about the major players in the market. Key players identified in this report are Pfizer Inc., F.Hoffmann-La Roche Ltd., Bausch Health Companies, Inc., Mylan, N.V., Teva Pharmaceutical Industries Ltd., H.Lundbeck A/S, Amneal Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd., Apotex Inc., and Aurobindo Pharma. Each of these players has been profiled in the report based on parameters such as company overview, financial overview, business strategies, product portfolio, Business segments and recent developments.

Report Segmentation:

• By Product
  • Alprazolam
  • Clonazepam
  • Diazepam
  • Lorazepam
  • Others (Clobazam, Temazepam, Midazolam, Chlordiazepoxide, Clorazepate, Estazolam, Flurazepam, Oxazepam, Triazolam, and Quazepam)
• By Application
  • Anxiety
  • Insomnia
  • Alcohol Withdrawal
  • Seizures
  • Others (Muscle spasm, panic disorders, general anesthesia, depression, Lennox-Gastaut syndrome, and maniac conditions)
• By Time of Action
  • Ultra-short Acting
  • Short Acting
  • Long Acting
• By Distribution Channel
  • Hospitals Pharmacies
  • Retail Pharmacies
  • Others (Online Pharmacies, Mail Pharmacies, and Home Care Pharmacies)
• By Region
  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of LATAM
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Research Methodology:

In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.

Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.

Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.

The study objectives of this report are:

• To analyze and study the global benzodiazepine drugs capacity, production, value, consumption, status (2014-2018) and forecast (2019-2026);
• Market value USD Million and volume Units Million data for each segment and sub-segment
• Focuses on the key benzodiazepine drugs manufacturers, to study the capacity, production, value, market share and development plans in future.
• Focuses on the global key manufacturers, to define, describe and analyze the market competition landscape, SWOT analysis.
• To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
• To identify significant trends and factors driving or inhibiting the market growth.
• To analyze the opportunities in the market for stakeholders by identifying the high growth segments.
• To strategically analyze each submarket with respect to individual growth trend and their contribution to the market
• To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
• To strategically profile the key players and comprehensively analyze their growth strategies.